Interpretation and application of world-wide safety data on diltiazem.
The safety of medicinal agents being introduced into the marketplace is of growing concern to consumers, health care providers, and regulatory agencies. Although there are ever increasing efforts to improve techniques for testing drugs, and for anticipating and confirming possible adverse effects, arrangements for monitoring and detecting adverse drug reactions are far from satisfactory. Some factors which need to be understood in order to appropriately interpret data include: maturation processes; pretesting affects, measuring instruments affects; selection bias; and the affects of differential experimental mortality. A safety profile has been presented for the calcium entry blocker diltiazem hydrochloride. Efforts were made to focus attention upon the source of safety information as it relates to the quality of the report. The data presented suggests that diltiazem hydrochloride has a low incidence of adverse experiences.
Quigley
M A
MA
White
K L
KL
McGraw
B F
BF
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D001552:Benzazepines / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000009:adverse effects*; D004347:Drug Interactions; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D011358:Product Surveillance, Postmarketing; D013806:Theophylline / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D013806:Theophylline; D004110:Diltiazem